270 related articles for article (PubMed ID: 23869775)
1. Orai1 and transient receptor potential channels as novel molecular targets to impair tumor neovascularization in renal cell carcinoma and other malignancies.
Moccia F; Dragoni S; Poletto V; Rosti V; Tanzi F; Ganini C; Porta C
Anticancer Agents Med Chem; 2014 Feb; 14(2):296-312. PubMed ID: 23869775
[TBL] [Abstract][Full Text] [Related]
2. Store-operated Ca2+ entry is remodelled and controls in vitro angiogenesis in endothelial progenitor cells isolated from tumoral patients.
Lodola F; Laforenza U; Bonetti E; Lim D; Dragoni S; Bottino C; Ong HL; Guerra G; Ganini C; Massa M; Manzoni M; Ambudkar IS; Genazzani AA; Rosti V; Pedrazzoli P; Tanzi F; Moccia F; Porta C
PLoS One; 2012; 7(9):e42541. PubMed ID: 23049731
[TBL] [Abstract][Full Text] [Related]
3. May the remodeling of the Ca²⁺ toolkit in endothelial progenitor cells derived from cancer patients suggest alternative targets for anti-angiogenic treatment?
Moccia F; Poletto V
Biochim Biophys Acta; 2015 Sep; 1853(9):1958-73. PubMed ID: 25447551
[TBL] [Abstract][Full Text] [Related]
4. Store-dependent Ca(2+) entry in endothelial progenitor cells as a perspective tool to enhance cell-based therapy and adverse tumour vascularization.
Moccia F; Dragoni S; Lodola F; Bonetti E; Bottino C; Guerra G; Laforenza U; Rosti V; Tanzi F
Curr Med Chem; 2012; 19(34):5802-18. PubMed ID: 22963562
[TBL] [Abstract][Full Text] [Related]
5. Angiogenesis and angiogenic inhibitors in renal cell carcinoma.
Sawhney R; Kabbinavar F
Curr Urol Rep; 2008 Jan; 9(1):26-33. PubMed ID: 18366971
[TBL] [Abstract][Full Text] [Related]
6. Tubulocystic renal cell carcinoma: is there a rational reason for targeted therapy using angiogenic inhibition? Analysis of seven cases.
Steiner P; Hora M; Stehlik J; Martinek P; Vanecek T; Petersson F; Michal M; Korabecna M; Travnicek I; Hes O
Virchows Arch; 2013 Feb; 462(2):183-92. PubMed ID: 23296808
[TBL] [Abstract][Full Text] [Related]
7. [The role of angiogenesis in renal carcinoma].
Bussolati B; Satolli MA; Camussi G
G Ital Nefrol; 2008; 25(3):297-305. PubMed ID: 18473301
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Sphingosine Phosphate Receptor 1 Signaling Enhances the Efficacy of VEGF Receptor Inhibition.
Fischl AS; Wang X; Falcon BL; Almonte-Baldonado R; Bodenmiller D; Evans G; Stewart J; Wilson T; Hipskind P; Manro J; Uhlik MT; Chintharlapalli S; Gerald D; Alsop DC; Benjamin LE; Bhatt RS
Mol Cancer Ther; 2019 Apr; 18(4):856-867. PubMed ID: 30787172
[TBL] [Abstract][Full Text] [Related]
9. Renal cell carcinoma: rationale and development of therapeutic inhibitors of angiogenesis.
Ebbinghaus SW; Gordon MS
Hematol Oncol Clin North Am; 2004 Oct; 18(5):1143-59, ix-x. PubMed ID: 15474339
[TBL] [Abstract][Full Text] [Related]
10. Importance of fibroblast growth factor receptor in neovascularization and tumor escape from antiangiogenic therapy.
Saylor PJ; Escudier B; Michaelson MD
Clin Genitourin Cancer; 2012 Jun; 10(2):77-83. PubMed ID: 22382009
[TBL] [Abstract][Full Text] [Related]
11. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391
[TBL] [Abstract][Full Text] [Related]
12. Resistance to angiogenesis inhibitors in renal cell carcinoma.
Tamaskar I; Dhillon J; Pili R
Clin Adv Hematol Oncol; 2011 Feb; 9(2):101-10. PubMed ID: 22173604
[TBL] [Abstract][Full Text] [Related]
13. Rac Signaling Drives Clear Cell Renal Carcinoma Tumor Growth by Priming the Tumor Microenvironment for an Angiogenic Switch.
Goka ET; Chaturvedi P; Lopez DTM; Lippman ME
Mol Cancer Ther; 2020 Jul; 19(7):1462-1473. PubMed ID: 32371578
[TBL] [Abstract][Full Text] [Related]
14. Ca2+ signalling in endothelial progenitor cells: a novel means to improve cell-based therapy and impair tumour vascularisation.
Moccia F; Lodola F; Dragoni S; Bonetti E; Bottino C; Guerra G; Laforenza U; Rosti V; Tanzi F
Curr Vasc Pharmacol; 2014 Jan; 12(1):87-105. PubMed ID: 22724469
[TBL] [Abstract][Full Text] [Related]
15. Anti-angiogenic therapy in renal cell carcinoma.
Sharma SG; Nanda S; Longo S
Recent Pat Anticancer Drug Discov; 2010 Jan; 5(1):77-83. PubMed ID: 19601920
[TBL] [Abstract][Full Text] [Related]
16. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model.
Drevs J; Hofmann I; Hugenschmidt H; Wittig C; Madjar H; Müller M; Wood J; Martiny-Baron G; Unger C; Marmé D
Cancer Res; 2000 Sep; 60(17):4819-24. PubMed ID: 10987292
[TBL] [Abstract][Full Text] [Related]
17. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
18. Anti-angiogenic therapy in renal cell cancer.
Srinivasan R; Armstrong AJ; Dahut W; George DJ
BJU Int; 2007 May; 99(5 Pt B):1296-300. PubMed ID: 17441927
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies.
Pircher A; Jöhrer K; Kocher F; Steiner N; Graziadei I; Heidegger I; Pichler R; Leonhartsberger N; Kremser C; Kern J; Untergasser G; Gunsilius E; Hilbe W
Oncotarget; 2016 Apr; 7(15):20109-23. PubMed ID: 26956051
[TBL] [Abstract][Full Text] [Related]
20. Anti-angiogenic targets in the treatment of advanced renal cell carcinoma.
Heng DY; Bukowski RM
Curr Cancer Drug Targets; 2008 Dec; 8(8):676-82. PubMed ID: 19075590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
